从资金流向上来看，当日动物保健板块主力资金净流出9984.08万元，游资资金净流出2164.17万元，散户 资金净流入1.21亿元。动物保健板块个股资金流向见下表： 证券之星消息，7月29日动物保健板块较上一交易日下跌0.5%，驱动力领跌。当日上证指数报收于 3609.71，上涨0.33%。深证成指报收于11289.41，上涨0.64%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 25.46 | 2.91% | 2.25万 | | 5731.13万 | | 688098 | 申联生物 | 6.85 | 1.33% | 10.41万 | | 7137.24万 | | 603566 | 普莱柯 | 15.23 | 0.40% | 5.03万 | | 7579.24万 | | 002688 | 金河生物 | 7.16 | 0.14% | 36.15万 | | 2.59亿 | | 688526 | 科前生物 | 17.2 ...

Group 1 - Senyuan Electric signed a strategic cooperation agreement with Xuchang Digital Supply Chain Management Co., aiming for annual business cooperation not exceeding 500 million yuan over 36 months [1] - CICC's subsidiary, CICC Wealth, reported a net profit of 987 million yuan for the first half of the year, with total assets of 193.37 billion yuan [2] - Shuangjie Electric expects a net profit of 100 million to 120 million yuan for the first half of the year, representing a year-on-year increase of 16.03% to 39.23% [3][4] - Shentong Technology reported a net profit of 64.28 million yuan for the first half of the year, a year-on-year increase of 111.09% [5] - Suqian Nongfa's net profit for the first half of the year decreased by 27.72% to 213 million yuan [6] Group 2 - Fuan Pharmaceutical expects a net profit decline of 39.95% to 53.81% for the first half of the year, estimating between 100 million to 130 million yuan [8] - Xingwang Yuda anticipates a net loss of 11 million to 21 million yuan for the first half of the year [9] - Pulaike received a new veterinary drug registration certificate for a vaccine aimed at preventing chicken diseases [10] - Yuandong Biological's ephedrine injection received a drug registration certificate for treating low blood pressure during anesthesia [11] - Suqian Liansheng's subsidiary obtained two invention patent certificates [12] Group 3 - Oke Technology signed a 176 million yuan equipment order with Jiangxi Tianhong New Materials [13] - Publishing Media announced the resignation of its chief accountant due to work changes [15] - Zhongxin Co. plans to use 40 million yuan of idle funds for cash management [16] - Huiyun Titanium plans to use up to 58 million yuan of idle convertible bond funds for cash management [18] - Haineng Technology intends to apply for a credit facility of up to 200 million yuan from a bank [20] Group 4 - Jiabiou expects a net profit increase of 57.61% for the first half of the year, estimating around 107 million yuan [21] - Nanjing Gaoke reported a 1185% year-on-year increase in contract sales area for the second quarter [22] - Shuguang Co. received approval for a specific stock issuance application [23] - Huadong Pharmaceutical's subsidiary received approval for a clinical trial of a new drug targeting advanced solid tumors [23] - Quicheng Co. plans to invest 900 million yuan in two new projects [25] Group 5 - Shenlian Biological's vaccine for avian adenovirus received a new veterinary drug registration certificate [26] - Rike Chemical signed a strategic cooperation framework agreement with Dongming Petrochemical [28] - Jincheng Pharmaceutical's subsidiary received a renewed tobacco production license [29] - Magmi Te's stock issuance application was accepted by the Shenzhen Stock Exchange [29] - Zhongyin Securities received approval to issue bonds totaling up to 14 billion yuan [29] Group 6 - Hewei Electric's executives plan to reduce their holdings by a total of 2.24% of the company's shares [44] - Guo Wang Xintong reported a net profit of 266 million yuan for the first half of the year, a decrease of 10.82% [45] - Guo Wang Xintong's subsidiary won a 966 million yuan tender from the State Grid [46] - Jicheng Electronics won contracts worth approximately 83.79 million yuan from the State Grid [48] - Helen Piano is planning a change of control, leading to a temporary stock suspension [48]

公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经中华人民共和国农业农村 部审查，批准公司及其他单位联合研制的禽腺病毒（Ⅰ群，4型）灭活疫苗（D N株）为新兽药，并核发《新兽药注册证书》，具体详情如下： 一、新兽药的基本信息 通用名：禽腺病毒（I群，4型）灭活疫苗（DN株） 证券代码：688098 证券简称：申联生物 公告编号：2025-025 申联生物医药（上海）股份有限公司 关于获批新兽药注册的自愿性披露公告 新兽药证号：（2025）新兽药证字74号 注册分类：三类 研制单位：贵州福斯特生物科技有限公司、贵州福斯特生物技术研究院、 东北农业大学、申联生物医药（上海）股份有限公司、江苏恒丰强生物技术有 限公司、天津市中升挑战生物科技有限公司 监测期：3年 主要成分：疫苗中含有灭活的禽腺病毒（Ⅰ群，4型）DN株。 作用与用途：用于预防禽腺病毒（Ⅰ群，4型）引起的禽腺病毒病。免疫产 生期为21日；7～21日龄鸡免疫期为4个月，22日龄及以上鸡免疫期为6个月。 用法与用量：颈部皮下或肌肉注 ...

Core Viewpoint - The company Shenyuan Biological has received approval for a new veterinary drug registration for its inactivated vaccine against Avian Adenovirus (Group I, Type 4), which will enhance its product offerings and sales capabilities [1] Group 1: Product Development - The inactivated vaccine, developed in collaboration with Guizhou Foster Biotechnology Co., is designed to prevent diseases caused by Avian Adenovirus (Group I, Type 4) [1] - The vaccine utilizes a whole virus culture process, preserving the natural conformation of the virus surface proteins [1] Group 2: Market Impact - The approval will enrich the company's animal vaccine product range and improve its sales scale and comprehensive customer service capabilities [1] - The product must still obtain a product approval number before it can be marketed and sold [1]

证券代码：688098 证券简称：申联生物 公告编号：2025-024 申联生物医药(上海)股份有限公司 关于获批兽药产品批准文号的自愿性披露公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》《兽药产品批准文号管理办法》等有关规定，经中华 人民共和国农业农村部审查，准予申联生物医药（上海）股份有限公司兰州分 公司生产猪瘟基因工程亚单位疫苗（CHO-133D），并核发兽药产品批准文号批 件，具体情况如下： 一、兽药产品批准文号基本情况 1、通用名称：猪瘟基因工程亚单位疫苗（CHO-133D） 4、有效期：2025年6月24日至2030年6月23日 二、兽药产品及其市场情况 猪瘟基因工程亚单位疫苗（CHO-133D）用于预防猪瘟。猪瘟（Infection with classical swine fever virus，简称 CSF）是由猪瘟病毒（CSFV）引起的一种高度急 性、热性、接触性传染病。该病以发病急、发生高热稽留和细小血管壁变性、全 身泛发性小点出血、脾梗死为特征。该病一年四季流行，可对养猪业造成 ...

Core Viewpoint - The company Shunlian Bio has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its genetically engineered subunit vaccine for swine fever, along with the issuance of the veterinary drug product approval number [1] Group 1 - The approval signifies a significant milestone for the company's product development in the veterinary vaccine sector [1] - The vaccine is expected to enhance the company's market position in the animal health industry [1] - This development may lead to increased revenue opportunities for the company in the future [1]

关于股份回购实施结果暨股份变动的公告 证券代码：688098 证券简称：申联生物 公告编号：2025-023 申联生物医药（上海）股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/11/26 | | --- | --- | | 回购方案实施期限 | 2024年11月26日~2025年5月25日 | | 预计回购金额 | 2,000万元~4,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | √用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 3,417,373股 | | 累计已回购股数占总股本比例 | 0.8322% | | 累计已回购金额 | 20,000,452.13元 | | 实际回购价格区间 | 5.47元/股~6.29元/股 | （一）2024年12月5日，公司首次实施回购股份。具体内容详见公司于2024年 12月6日在上海证券交易所网站（www.sse.com.cn）上披露的《关于以集中竞 ...

Core Viewpoint - The company has approved a share repurchase plan aimed at enhancing employee stock ownership and incentivizing through equity incentives or convertible bond conversions [1] Summary by Relevant Sections Share Repurchase Plan - The company plans to repurchase shares with a budget of 20 million to 40 million yuan through centralized bidding [1] - The board approved this plan on November 25, 2024 [1] Repurchase Details - As of May 23, 2025, the company has repurchased a total of 3.4174 million shares, which represents 0.8322% of the total share capital [1] - The repurchase price range was between 5.47 yuan and 6.29 yuan per share [1] - The total funds used for the repurchase amounted to 20.0005 million yuan, excluding transaction fees [1] Future Use of Repurchased Shares - The repurchased shares will be held in a dedicated securities account for future plans and must be utilized or legally processed within the stipulated timeframe [1]

国浩律师（上海）事务所 法律意见书 本所律师同意将本法律意见书作为公司本次股东大会的必备文件公告，并依 法对本所出具的法律意见承担责任。 本所律师已经对与出具法律意见书有关的所有文件材料及证言进行审查判 断，并据此出具法律意见如下： 一、本次股东大会的召集、召开程序 国浩律师（上海）事务所 关于申联生物医药（上海）股份有限公司 2024 年年度股东大会的法律意见书 致：申联生物医药（上海）股份有限公司 申联生物医药（上海）股份有限公司（以下简称"公司"）2024 年年度股东大 会（以下简称"本次股东大会"）现场会议定于 2025 年 5 月 20 日下午 14:30 在上 海市闵行区江川东路 48 号公司综合楼一楼会议室召开，国浩律师（上海）事务 所（以下简称"本所"）接受公司的委托，指派本所律师出席会议，并依据《中华 人民共和国证券法》、《中华人民共和国公司法》、《申联生物医药（上海）股 份有限公司章程》（以下简称《公司章程》）出具本法律意见书。 本所律师已经按照有关法律、法规的规定对本次股东大会召集、召开程序是 否合法及是否符合《公司章程》、股东大会召集人资格的合法有效性、出席会议 人员资格的合法有效性和 ...

证券代码：688098 证券简称：申联生物 公告编号：2025-022 申联生物医药（上海）股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 05 月 20 日 （二） 股东大会召开的地点：上海市闵行区江川东路 48 号公司综合楼一楼 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股 东及其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 55 | | --- | --- | | 普通股股东人数 | 55 | | 2、出席会议的股东所持有的表决权数量 | 221,320,600 | | 普通股股东所持有表决权数量 | 221,320,600 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 54.3482 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 54.3482 | ...